TD Cowen Issues Positive Forecast for Illumina (NASDAQ:ILMN) Stock Price

Illumina (NASDAQ:ILMN) had its price target upped by research analysts at TD Cowen from $192.00 to $210.00 in a research report issued on Friday,Benzinga reports. The brokerage presently has a “hold” rating on the life sciences company’s stock. TD Cowen’s price objective indicates a potential upside of 5.17% from the company’s previous close.

Several other brokerages also recently commented on ILMN. Sanford C. Bernstein reiterated a “market perform” rating and set a $215.00 target price on shares of Illumina in a research note on Friday. Royal Bank Of Canada restated an “outperform” rating and issued a $230.00 price target on shares of Illumina in a research note on Friday. JPMorgan Chase & Co. raised Illumina from a “neutral” rating to an “overweight” rating and raised their price target for the company from $125.00 to $185.00 in a report on Wednesday, June 10th. Citigroup raised their price target on Illumina from $80.00 to $95.00 and gave the company a “sell” rating in a report on Monday, May 4th. Finally, Daiwa Securities Group upgraded shares of Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 price objective on the stock in a report on Thursday, May 14th. Nine investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $172.82.

Illumina Stock Performance

NASDAQ:ILMN traded down $5.41 during mid-day trading on Friday, hitting $199.68. The stock had a trading volume of 2,260,349 shares, compared to its average volume of 1,889,744. Illumina has a twelve month low of $88.00 and a twelve month high of $205.47. The stock has a market cap of $30.21 billion, a price-to-earnings ratio of 36.39, a PEG ratio of 2.88 and a beta of 1.47. The company’s 50 day simple moving average is $175.49 and its 200 day simple moving average is $146.83. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.36 and a current ratio of 1.75.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Thursday, July 30th. The life sciences company reported $1.31 EPS for the quarter, topping analysts’ consensus estimates of $1.23 by $0.08. The business had revenue of $1.16 billion during the quarter, compared to analysts’ expectations of $1.13 billion. Illumina had a return on equity of 31.01% and a net margin of 19.42%.Illumina’s quarterly revenue was up 9.4% on a year-over-year basis. During the same quarter last year, the company posted $1.19 earnings per share. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. On average, equities research analysts forecast that Illumina will post 5.22 earnings per share for the current year.

Insider Buying and Selling at Illumina

In other Illumina news, SVP Patricia Leckman sold 783 shares of the business’s stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $162.59, for a total value of $127,307.97. Following the completion of the sale, the senior vice president owned 21,259 shares of the company’s stock, valued at $3,456,500.81. The trade was a 3.55% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith A. Meister sold 235,000 shares of the stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $163.63, for a total transaction of $38,453,050.00. Following the transaction, the director owned 2,830,452 shares in the company, valued at approximately $463,146,860.76. The trade was a 7.67% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 1,003,769 shares of company stock valued at $155,710,908 in the last quarter. Company insiders own 2.90% of the company’s stock.

Institutional Investors Weigh In On Illumina

Hedge funds and other institutional investors have recently made changes to their positions in the business. Capital World Investors boosted its stake in shares of Illumina by 0.6% in the fourth quarter. Capital World Investors now owns 20,101,173 shares of the life sciences company’s stock valued at $2,636,483,000 after buying an additional 124,323 shares during the period. State Street Corp increased its stake in Illumina by 3.2% during the 4th quarter. State Street Corp now owns 6,190,114 shares of the life sciences company’s stock worth $811,895,000 after acquiring an additional 190,324 shares during the period. WCM Investment Management LLC increased its stake in Illumina by 45.5% during the 1st quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company’s stock worth $715,579,000 after acquiring an additional 1,851,848 shares during the period. AQR Capital Management LLC raised its holdings in Illumina by 30.3% in the 4th quarter. AQR Capital Management LLC now owns 4,426,126 shares of the life sciences company’s stock valued at $580,531,000 after acquiring an additional 1,028,099 shares in the last quarter. Finally, Geode Capital Management LLC raised its holdings in Illumina by 4.8% in the 4th quarter. Geode Capital Management LLC now owns 2,869,047 shares of the life sciences company’s stock valued at $375,260,000 after acquiring an additional 130,139 shares in the last quarter. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Illumina

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Illumina reported second-quarter revenue of $1.16 billion, up approximately 9.5% year over year, while non-GAAP EPS of $1.31 exceeded the $1.23 analyst consensus. Clinical demand and continued NovaSeq X placements were key growth drivers. Illumina Q2 2026 Financial Results
• Positive Sentiment: Management raised full-year 2026 revenue guidance to $4.60 billion–$4.64 billion and non-GAAP EPS guidance to $5.30–$5.40, above the prior outlook and roughly ahead of consensus expectations. Illumina Q2 Outlook
• Positive Sentiment: Stifel Nicolaus raised its price target from $155 to $225 and upgraded the stock to “buy,” citing improved growth prospects. Eli Lilly also joined Illumina’s Billion Cell Atlas initiative, potentially strengthening the company’s position in genomic data and drug discovery. Stifel Price Target
• Neutral Sentiment: Analyst views remain mixed: the recent median price target was $185, below the stock’s recent trading level, although several firms maintain targets near $200.
• Neutral Sentiment: Institutional positioning was divided, with 375 investors adding shares and 402 reducing positions in the latest reported quarter.
• Negative Sentiment: Greater China revenue fell 12% year over year, reflecting continuing China-related restrictions and demand pressure.
• Negative Sentiment: Full-year non-GAAP operating-margin guidance remained unchanged at 23.4%–23.6%, while management indicated that year-over-year NovaSeq X instrument-placement growth may moderate in the second half.
• Negative Sentiment: Reported insider activity was heavily weighted toward selling: 41 sales versus one purchase over the past six months, including substantial sales by Keith Meister. This may add to investor caution, although insider transactions can reflect personal liquidity needs.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.